EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion

Francesca Sillito, Elisa Armbrecht, Aideen T O'Neill, Andrew McIntyre, Melville Nyatondo, Angelika Holler, Lauren A Callender, Sian M Henson, Hans Stauss, Ronjon Chakraverty iD

The Journal of Immunology · 04.08.2026 · 215 (8)

DOI: 10.1093/jimmun/vkag206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 07.08.2026. Verfasst von Francesca Sillito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, University College London, London, United Kingdom. Hauptthemen laut MEDLINE: Mechanistic Target of Rapamycin Complex 1, CD4-Positive T-Lymphocytes, Immunotherapy, Adoptive. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is substantial interest in developing novel engineering strategies to promote the sustained metabolic fitness of therapeutic T cells. We previously showed that overexpression of RAS homologue enriched in brain (RHEB), a positive regulator of mammalian target of rapamycin complex 1 (mTORC1), promotes aerobic glycolysis and increases the anti-tumor functions of effector CD8+ T cells. To address whether these effects are conserved in CD4+ T cells, we have now examined how enforced activation of mTORC1 activity affects CD4+ T cell differentiation and function. Rheb overexpression induced a more balanced metabolic shift in CD4+ T cells than in CD8+ T cells, with increases in both oxidative phosphorylation and aerobic glycolysis. Although Rheb overexpression initially increased CD4+ T cell activation and proliferation in vitro, the underlying population architecture was complex, involving a shift to both more proliferative, cytotoxic-like cell states as well as more quiescent cell clusters characterised by counter-regulation of mTORC1 activity. Following adoptive transfer, tumor antigen-specific Rheb-transduced CD4+ T cells showed greater persistence but were less efficient than controls in eliminating tumor. This functional deficiency could be explained by a greater propensity of persisting Rheb-transduced CD4+ T cells to develop features of immune exhaustion, as evidenced by expression of multiple co-inhibitory receptors and impaired proliferation upon tumor rechallenge. Together, these data demonstrate the dynamic population response to tuning of T cell mTORC1 and the need to separately appraise cellular outputs of therapeutic CD4+ versus CD8+ T cells when metabolic pathways are manipulated by the same method.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mechanistic Target of Rapamycin Complex 1CD4-Positive T-LymphocytesImmunotherapy, AdoptiveAnimalsRas Homolog Enriched in Brain ProteinT-Cell ExhaustionMiceCD8-Positive T-LymphocytesLymphocyte ActivationCell ProliferationCell DifferentiationHumansMice, Inbred C57BL

Stichwörter der Autor:innen

CD4+ T cellexhaustionimmunotherapymTORC1

Substanzen

Mechanistic Target of Rapamycin Complex 1Ras Homolog Enriched in Brain ProteinRheb protein, mouse

Autor:innen und Institutionen

  • Cancer Institute, University College London, London, United Kingdom.
  • Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.
  • Institute of Immunity and Transplantation, University College London, London, United Kingdom.
  • Translational Medicine and Therapeutics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University London, London, United Kingdom.

ORCID-Profile: Ronjon Chakraverty

Förderung

  • Cancer Research UK
  • Medical Research Council

Zitieren

APA

Sillito, F., Armbrecht, E., O'Neill, A. T., McIntyre, A., Nyatondo, M., Holler, A., Callender, L. A., Henson, S. M., Stauss, H., & Chakraverty, R. (2026). Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion. The Journal of Immunology, 215(8). https://doi.org/10.1093/jimmun/vkag206

Vancouver

Sillito F, Armbrecht E, O'Neill AT, McIntyre A, Nyatondo M, Holler A, et al. Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion. The Journal of Immunology. 2026;215(8). doi:10.1093/jimmun/vkag206

BibTeX
@article{Sillito2026,
  author = {Sillito, Francesca and Armbrecht, Elisa and O'Neill, Aideen T and McIntyre, Andrew and Nyatondo, Melville and Holler, Angelika and Callender, Lauren A and Henson, Sian M and Stauss, Hans and Chakraverty, Ronjon},
  title = {Enforcing mTORC1 activity in therapeutic CD4+ T cells promotes persistence but eventual immune exhaustion},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {8},
  doi = {10.1093/jimmun/vkag206}
}
Kostenlos starten →